Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients With Advanced/Metastatic Solid Tumors

NCT05718895 is registered in ClinicalTrials.gov with Antengene Biologics Limited as lead sponsor.

NCT NCT05718895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05718895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients With Advanced/Metastatic Solid Tumors
Lead sponsor
Antengene Biologics Limited
Phase
Phase 1
Overall status
Recruiting
Start date
March 27, 2023
Completion date
December 30, 2027
Enrollment
156 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/metastatic solid tumors